Clinical Trials
27 trialsA Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
Memorial Sloan Kettering Cancer Center
ZGR
Institute of Hematology & Blood Diseases Hospital, China
Obinutuzumab in Marginal Zone Lymphoma
University of Ulm
CLL17
German CLL Study Group
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Weill Medical College of Cornell University
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
University of California, Davis
R-Pola-Glo
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
M.D. Anderson Cancer Center
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Dana-Farber Cancer Institute
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab
Weill Medical College of Cornell University
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
Thomas Jefferson University
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
M.D. Anderson Cancer Center
AVO
Dana-Farber Cancer Institute
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Memorial Sloan Kettering Cancer Center
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
SAVE
Dana-Farber Cancer Institute
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
Memorial Sloan Kettering Cancer Center
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Emory University
CLL2-BZAG
German CLL Study Group
FLUORO
Olivia Newton-John Cancer Research Institute
ZGR in TN CLL
Institute of Hematology & Blood Diseases Hospital, China
LEVERAGE
Peter MacCallum Cancer Centre, Australia